Boston, MA – January 16, 2024 – PathAI, a leading AI-powered precision pathology company, has concluded a year marked by significant growth and advancements. The company developed and launched over 20 new AI products across oncology, MASH/MASLD1 and IBD; launched the AISight® image management system (IMS); distributed the AISight platform and IMS to a growing footprint of more than 50 labs globally; expanded clinical trial services to encompass MASH/MASLD, IBD and oncology; and honed its leadership team to drive biopharma business, regulatory strategy, and growth initiatives. Moreover, PathAI established key partnerships, presented new data at major industry conferences, and was recognized through several industry awards. The culmination of these 2023 achievements serves to further revolutionize the field of pathology, bringing more AI-driven tools to drug development and diagnostics.
Revolutionary Product Launches and Expanded Services
In 2023, PathAI launched over 20 cutting edge AI products. PathExplore TM, unveiled in April, is the world's first structured, standardized, and scalable panel of human interpretable features (HIFs). It delivers unparalleled insight into the tumor microenvironment (TME) from H&E whole-slide images across eight oncology disease indications (with more to follow). This AI-powered tool quantifies the TME with spatially contextualized, single-cell resolution, providing a transformative perspective for oncology drug developers delving into the intricacies of histopathology and the TME.
PathAI then introduced IBD ExploreTM, an AI-powered histopathology panel unlocking profound insights into ulcerative colitis. This was followed by NASH ExploreTM, a tailored panel designed to elevate clinical trials support for MASH/MASLD. These products are set to redefine the landscape of targeted drug development for the respective disease areas.
AIM-PD-L1™and AIM-HER2™ Breast Cancerwere developed to enable reproducible biomarker quantification and disease severity assessment; ArtifactDetectfor automated quality control; AIM-TumorCellularity,for automated quantification of tissue area and percent tumor nuclei; and TumorDetectfor automated assessment and quantification of tumor across diverse tissue types. Additionally, the AISight digital pathology IMS was launched and distributed to more than 50 leading academic medical centers, health systems, reference laboratories, and independent pathology organizations as part of PathAI’s Early Access Programto gather real world evidence on the use of digital pathology tools to advance precision medicine.
In the fall, PathAI announced the expansion of its BioPharma Laboratory Services, reinforcing the ability to offer customers quality, scalable and flexible pathology services that can be seamlessly combined with digital pathology and AI. Capitalizing on the 30-year history of delivering high quality pathology services in the PathAI Diagnostics clinical laboratory (formerly known as Poplar Healthcare), PathAI offers biopharma partners a comprehensive, GCP/GCLP compliant histology and digital pathology lab to support prospective clinical trials across oncology, liver, and gastrointestinal indications.
Forging New Partnerships
To pave the way for new products and solutions, PathAI solidified strategic partnerships with other leaders in the life science space. Together with ConcertAI, PathAI launched a first-in-class quantitative histopathology and curated clinical real-world data solution combining PathExplore HIFs with ConcertAI’s Patient360™ and RWD360™ products to support life sciences partners in exploring novel hypotheses.
With a focus on enabling the laboratory community with digital and AI solutions, a multiyear distribution agreement with Agilent Technologies was launched to distribute the AISight platform along with AIM-PD-L1 NSCLC, an algorithm for PD-L1 quantification in non-small cell lung cancer (NSCLC), to anatomic pathology laboratories.
And in August, the Foundation for the National Institutes of Health’s Biomarkers Consortium – Mucosal Healing in Ulcerative Colitics project team selected PathAI as their exclusive technology partnerto further the study of mucosal healing, bring AI-assisted precision to disease assessment, and drive cutting-edge research to facilitate the development of new therapies for ulcerative colitis.
Accelerating Research
PathAI showcased a total of 31 posters, six oral presentations, and eight manuscripts at high-profile conferences and events in 2023, including the American Association for Cancer Research, the American Association for the Study of Liver Diseases, the Society for Immunotherapy in Cancerand the San Antonio Breast Cancer Symposium.
The PathExplore Data Access Program was launched in July 2023, offering academic researchers access to PathExplore’s quantitative histopathology data, which can then be linked to molecular and clinical outcomes data from The Cancer Genome Atlas (TCGA). Since then, more than 13 projects across six institutions have been initiated to investigate multi-modal insights on patient response, drug pathways, and potential novel biomarkers.
Expanding Expertise
In 2023, PathAI not only fortified its product arsenal but also elevated its expertise with the addition of several executives. Dr. Hisani Madison, Franchise Head of Precision Oncology, brings a wealth of knowledge in regulatory strategy, further solidifying PathAI's position at the forefront of precision diagnostics. Dr. Nick Anderson, Vice President of Regulatory Affairs, brings over a decade of experience from the U.S. Food and Drug Administration, propelling PathAI to new heights in digital pathology regulation. Matt Grow joined PathAI as President of Biopharma and Chief Business Officer, bringing deep expertise in biopharma business development and commercial operations.
Beyond Boundaries
PathAI's pursuit of excellence in 2023 is a testament to the company's dedication to providing customers with unmatched end-to-end pathology solutions that will simplify critical work, accelerate clinical trials, and improve patient outcomes by providing exceptional insights to inform diagnostics and care.
“This past year was unrivaled in the products we brought to market, and I’m proud of our exceptional team for their efforts to empower our customers with data-driven AI products to propel a new phase of precision medicine,” said Andy Beck, M.D., Ph.D., Chief Executive Officer and Co-founder of PathAI. “In 2023, we saw a significant increase in our velocity of platform and product releases for our AISight platform and menu of AI products, and we are thrilled to enter 2024 with robust capabilities to serve our partners in diagnostics and drug development.”
PathAI’s 2024 focus areas will include leveraging the latest machine learning (ML) methods to enhance AI product development; scaling use of the growing AI product portfolio to accelerate biomarker discovery and development with partners in pharma and academia; incorporating AI-powered pathology in prospective clinical development programs and medical devices (both IVD and CDx); and continuing to empower diagnostic pathology laboratories with digital pathology and AI product solutions via the PathAI platform.
Awards and Recognitions
PathAI wrapped up 2023 with prestigious accolades and awards, including spots on the Forbes AI 50 list,the Fortune 50 AI Innovators list, and the Deloitte Technology Fast 500. The company was also recognized as one of XB-100’stop deep tech companies.
Chief Executive Officer and co-founder Andy Beck was recognized on the EY Entrepreneur of the Year list, and Slice of Healthcare 50 Under 50. Chief Operating Officer Tiffany Freitas was also honored as one of Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023.
As the new year begins, PathAI is looking ahead to creating and refining products, tools, and services to meet the evolving needs of biopharma and laboratory partners. This continuing work promises further advancements that will amplify efficiency, accuracy, and speed in the pursuit of therapeutic efficacy and accelerated drug development for complex diseases.
[1] MASH: metabolic dysfunction-associated steatohepatitis; MASLD: metabolic dysfunction-associated steatotic liver disease
[2]AISight, PathExplore, IBD Explore, NASH Explore, AIM-PD-L1, AIM-HER2, AIM-TumorCellularity, ArtifactDetect, and TumorDetect are For Research Use Only. Not for use in diagnostic procedures.
About PathAI
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Their AI-powered models are rigorously trained and validated with data from more than 15 million annotations and are used to optimize the analysis of pathology samples to improve efficiency and accuracy, while also accelerating drug development. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified laboratory in Memphis, TN. For more information, please visit www.pathai.com.
Media Contact
Jordan Bouclin
SVM Public Relations and Marketing Communications
pathai@svmpr.com
(401) 490-9700